Since 2020, new high-quality studies and meta-analyses have refined our understanding of the vitamin B12 status in vegan and general populations. These findings clarify the risks associated with both low and high serum B12 levels, as well as the complex role of functional markers, including methylmalonic acid (MMA) and homocysteine. This update reviews what's changed, what's solid, and what remains uncertain.
Vitamin B12 is crucial for DNA synthesis, red blood cell formation, and neurological function. Deficiency can lead to anemia, cognitive decline, and irreversible nerve damage.
B12 (cobalamin) is not made by plants or animals but by certain bacteria in soil, which is then consumed by animals. The bacteria accumulate in the gut where they produce B12. Some fermented foods and algae (e.g., spirulina) contain B12-like compounds, but most are inactive analogues that the body cannot use and may even block absorption of true B12.
For this reason, experts agree that fortified foods and supplements are the only reliable sources for vegans.
Unlike many nutrients, B12's safety margin is unusually wide: Deficiency is clearly harmful, while excess from supplements shows no consistent evidence of toxicity.
Low serum or functional B12 levels, common among people who avoid animal products without supplementing, are likely associated with increased mortality and neurological complications.
Prolonged deficiency can cause irreversible nerve damage (paresthesia, balance problems, and cognitive decline) and megaloblastic anemia, which impairs oxygen transport and increases cardiac strain. Elevated homocysteine, a byproduct of low B12, is also likely linked with higher cardiovascular and cerebrovascular risk.
Vegans aren't solely at risk. Older adults, people with digestive disorders, and those taking medications like metformin or proton pump inhibitors (PPIs) are also vulnerable.
The NHANES cohort (Wolffenbuttel et al., BMC Medicine, 2020) found that individuals with serum B12 < 140 pmol/L had a 39% higher risk of all-cause mortality (HR 1.39, 95% CI 1.08–1.78) and a 64% higher risk of cardiovascular mortality (HR 1.64, 95% CI 1.08–2.47) compared with mid-range levels.
The authors proposed that in low B12 states, mortality and accompanying telomere shortening may be driven by elevated homocysteine and oxidative stress. This mechanistic link is plausible but requires further validation.
Together, these findings reinforce that low B12 is more than a biomarker; it can be a biological driver of disease processes, especially when uncorrected over time.
B12 supplementation reliably lowers homocysteine, but large trials show, about as likely as not, that this translates into reduced cardiovascular events (Clarke R et al., 2010). More recent analyses suggest this may be due to confounding factors, particularly the form of B12 used.
Cyanocobalamin, the most common synthetic form of B12, may pose a small risk for people with renal impairment due to cyanide accumulation (Koyama et al., 1997), whereas methylcobalamin or hydroxocobalamin appear to be safer alternatives, particularly for those with kidney impairment (Capelli et al., 2019).
Several population studies have observed a U-shaped relationship between serum B12 and mortality, suggesting that both very low and very high levels correlate with increased risk. However, elevated B12 likely reflects underlying health conditions rather than toxicity from supplementation.
In the NHANES cohort (Wolffenbuttel et al., BMC Medicine, 2020), individuals with serum B12 > 700 pmol/L had higher cardiovascular mortality (HR ≈ 1.4–1.5). Similar studies lacked detailed dietary or supplement information, meaning the observed association could also reflect confounding factors such as higher animal-product consumption or pre-existing illnesses, including liver, kidney, or inflammatory diseases.
Follow-up analyses indicate that serum B12 tends to rise during chronic illness due to hepatic release, altered clearance, or increased levels of B12-binding proteins, not because of excessive intake. In other words, high circulating B12 is likely a marker of disease rather than a cause.
The study authors summarized this:
Low serum B12 < 140 pmol/L remained significantly associated with all-cause and cardiovascular mortality, while high serum B12 > 700 pmol/L was associated with increased cardiovascular mortality only. In none of the adjusted models could we demonstrate a relationship between serum B12 concentrations and cancer-related mortality.
They further explained:
Elevated serum B12 was associated with severity of disease in acute-on-chronic liver failure, interstitial renal disease, liver cirrhosis, hepatitis, and liver metastases, and proved to be a marker of poor liver function, but not a predictor of mortality after admission to an intensive care unit.
Taken together, these findings indicate that high serum B12 usually reflects underlying health issues. Potential mechanisms include increased production of B12-binding proteins, release of stored B12 from damaged liver cells, or reduced hepatic clearance. As the authors concluded:
There is nothing in those reports that indicates causality in the direction of a priori raised serum B12 leading to increased mortality […] While our findings confirm a U-shaped association, they lend no support to the suggestion that high serum B12 concentrations per se are harmful or detrimental.
Overall, the evidence suggests that B12 supplementation likely does not directly cause toxicity or increase mortality risk. Persistently high serum B12 should prompt clinical evaluation for underlying conditions, but does not warrant automatic discontinuation of supplementation, especially for individuals at risk of deficiency.
Randomized controlled trials using B12 doses from 20 mcg to 2000 mcg/day show no consistent increase in all-cause or cancer mortality (Calderon-Ospina et al., 2020). The NIH has not set an upper limit, citing low potential for toxicity:
The FNB did not establish a UL for vitamin B12 because of its low potential for toxicity. Even at large doses, vitamin B12 is generally considered to be safe because the body does not store excess amounts.
Typical supplementation for vegans (25–100 mcg/day) safely maintains functional sufficiency. Extremely high serum levels (>700 pmol/L) should prompt clinical evaluation for hepatic, renal, or hematologic conditions rather than automatic discontinuation of supplementation.
Traditional assessments of vitamin B12 status only rely on serum levels, but this can be misleading. Serum B12 reflects total circulating vitamin, not how effectively the body uses it. It is possible to show “normal” serum B12 while experiencing functional deficiency, where the vitamin isn’t properly utilized.
This 2024 study (Niklewicz et al., 2024) found vegans often had elevated homocysteine and lower functional B12 despite normal serum levels. Supplementation, however, significantly improved these markers, particularly homocysteine and MMA, as confirmed by a meta-analysis from the University of East Anglia (UEA).
Newer guidelines emphasize functional markers: homocysteine, methylmalonic acid (MMA), and holotranscobalamin (holoTC), which provide a clearer picture of B12 activity.
When looking at serum B12 alone, here's a suggested framework:
Because plants do not provide reliable sources of vitamin B12, supplementation is essential, especially for vegans or those with poor absorption.
Effective oral regimens include small divided doses (e.g., ~4.5 mcg taken three times per day), daily doses of 25–100 mcg, or weekly doses of 1,000-2,000 mcg, and 1,000 mcg for adults over 65. Clinical trials show that various strategies can improve B12 markers; no single regimen is clearly superior.
Methylcobalamin or hydroxocobalamin is preferred for those with kidney concerns. Fortified foods, such as enriched plant milks, cereals, nutritional yeast, and some meat alternatives, can complement supplements but are unlikely to meet needs alone.
Older adults may need higher or more frequent doses due to reduced absorption. Efficiency also drops as single-dose intake rises, which supports either divided daily doses or large weekly ones (Fernandes S et al., 2024). A dose-finding trial in older adults found that several hundred to 1,000 mcg daily was required to normalize MMA and holoTC.
Fortified foods can also play a supportive role, though they rarely provide enough on their own. Many plant milks, cereals, nutritional yeast, and some meat alternatives are enriched with vitamin B12, typically offering 1–4 mcg per serving. When used consistently, these foods can contribute meaningfully to daily intake and help maintain steady blood levels. However, because fortification levels vary between products, diligence is key.
A dose-response RCT (by Huang et al., 2024) also showed that roasted purple laver (nori) can raise serum B12 (~59 pmol/L over four weeks at 5 g/day) and improve holoTC and homocysteine. Still, B12 content in nori varies by brand and harvest season, so it should be viewed as a complement, not a replacement, for supplements.
Definitions of “low” and “high” serum B12 still vary across studies, and few datasets include detailed dietary or supplement data. This complicates direct comparisons and limits conclusions about causality. Future research should focus on integrating functional markers and standardized thresholds to improve interpretability.
